1. What Happened?
Inbiogen reported revenue of ₩1.8 billion, an operating loss of ₩1 billion, and a net profit of ₩1.1 billion for the first half of 2025. While exceeding revenue expectations and achieving net profit are positive signs, the continued operating loss raises concerns.
2. Why the Profit, and How?
The primary driver of the net profit is equity method income from its investment in Bident. This reliance on investment income rather than core business performance warrants caution. Despite increased revenue, the kiosk business continues to operate at a loss, and the F&B segment remains weak.
3. Should You Invest in Inbiogen Now?
The short answer is to proceed with caution. While the kiosk business shows growth potential, its profitability remains uncertain, and the heavy reliance on Bident investment poses a significant risk. High stock volatility also adds to investor concerns.
4. Investor Action Plan
- Monitor kiosk business profitability improvements
- Track Bident’s financial performance and health
- Assess cost management and operational efficiency gains
Investing in Inbiogen requires careful consideration. Thoroughly evaluate the key points outlined above before making any investment decisions.
Frequently Asked Questions
What are Inbiogen’s main businesses?
Inbiogen primarily focuses on the kiosk business and also operates in the F&B sector. They are currently exploring diversification into AI, VR, bio, and blockchain technologies.
What were Inbiogen’s 2025 semi-annual results?
They reported ₩1.8 billion in revenue, a ₩1 billion operating loss, and a ₩1.1 billion net profit. While revenue exceeded expectations, the operating loss continues. Net profit was driven by equity method investment income.
What are the key risks of investing in Inbiogen?
Investors should be aware of the company’s high dependence on investment income and the uncertain profitability of its core kiosk business. High stock volatility is also a risk factor.
Leave a Reply